Want to see ZBH full AI Analyst Report?
ZBH Stock Chart & Stats
$100.24
$1.70(1.90%)
At close: 4:00 PM EDT
$100.24
$1.70(1.90%)
Day’s Range― - ―
52-Week Range$79.12 - $106.88
Previous CloseN/A
Volume1.25M
Average Volume (3M)2.14M
Market Cap
$18.87B
Enterprise Value$23.68K
Total Cash (Recent Filing)$410.00M
Total Debt (Recent Filing)$7.48B
Price to Earnings (P/E)23.7
Beta0.48
Next Earnings
Nov 04, 2026EPS Estimate
1.88Next Dividend Ex-DateN/A
Dividend Yield0.98%
Share Statistics
EPS (TTM)4.13
Shares Outstanding190,737,690
10 Day Avg. Volume1,316,326
30 Day Avg. Volume2,135,058
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.40
Price to Sales (P/S)2.16
P/FCF Ratio12.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$106.07Price Target Upside5.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)8.53
Revenue Forecast (FY)$8.60B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationImproving operating cash flow and free cash flow provide durable funding for research, manufacturing capacity, acquisitions and shareholder returns, reducing reliance on external financing while supporting strategic flexibility.
Technology And Hip AdoptionStrong adoption of hip implants, robotics and surgical-enabling products can deepen surgeon relationships, increase procedural content and improve Zimmer Biomet's competitive position in technology-led orthopedic care.
Broad Product InnovationA substantial product pipeline and differentiated offerings support future revenue opportunities across orthopedic procedures. Continued innovation can refresh the portfolio, address clinical needs and defend market share over multiple years.
Bears Say
Sustained Margin PressureInvestment in the U.S. commercial organization and higher manufacturing costs are compressing profitability. If these costs persist longer than productivity gains, weaker operating leverage could limit earnings and cash-flow growth.
Pricing And Reimbursement RiskImplant pricing pressure and reimbursement changes can structurally reduce revenue per procedure and gross margins. These risks may intensify competitive pressure and make it harder for innovation and mix improvements to offset erosion.
Knee And China WeaknessKnees remain a core reconstructive category, so weak performance in that franchise can weigh on portfolio growth. China and emerging-market weakness also limits geographic diversification and may prolong difficult comparisons.
Zimmer Biomet Holdings News
ZBH FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Zimmer Biomet Holdings lowest stock price was $79.12 and its highest was $106.88 in the past 12 months.
What is Zimmer Biomet Holdings’s market cap?
Zimmer Biomet Holdings’s market cap is $18.87B.
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 59 days.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Aug 05, 2026. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings pays a Quarterly dividend of $0.24 which represents an annual dividend yield of 0.98%. See more information on Zimmer Biomet Holdings dividends here
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is 1.88.
How many shares outstanding does Zimmer Biomet Holdings have?
Zimmer Biomet Holdings has 190,737,690 shares outstanding.
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of $2.07 in its last earnings report, beating expectations of $2.01. Following the earnings report the stock price went up 2.453%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Currently, no hedge funds are holding shares in ZBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zimmer Biomet Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$106.07 (5.81% Upside)
$106.07 (5.81% Upside)
Blogger Sentiment
Bullish
ZBH Sentiment 71%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.40%
12-Months-Change
Fundamentals
Return on Equity
0.98%
Trailing 12-Months
Asset Growth
-0.29%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
ZBH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple strong operational and financial positives — revenue beat, raised guidance, robust cash generation, rapid technology and hip product adoption, successful Paragon integration and a sizable buyback — while acknowledging near-term headwinds including margin pressure from investment and manufacturing costs, pricing erosion risk, weakness in knees and China, and some supply constraints. Management framed 2026 as a transitional year with confidence that investments and go-to-market changes will improve execution and performance into 2027.View all ZBH earnings summariesZBH Net sales Breakdown
40.36% Knees
25.43% Hips
26.12% S.E.T
8.09% Technology & Data, Bone Cement and Surgical
ZBH Stock 12 Month Forecast
Average Price Target
$106.07
▲(5.81% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
46.93% Mutual Funds
13.25% Other Institutional Investors
11.11% Public Companies and
Individual Investors